Maverick Therapeutics is now part of Takeda. Follow us at https://www.linkedin.com/company/takeda-pharmaceuticals/ Maverick Therapeutics is pioneering the next generation of redirected T-cell targeted immunotherapies. Maverick’s highly innovative platform, COBRA™, is the most advanced bispecific T-cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.
Location: United States, California, Brisbane
Employees: 10001+
Total raised: $125M
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.01.2017 | - | $125M | - |
Mentions in press and media 5
| Date | Title | Description |
| 09.03.2021 | Takeda erwirbt Maverick Therapeutics zur Weiterentwicklung von T-Zell-Engager-Therapien für solide Tumore und Erweiterung des neuartigen Immunonkologie-Portfolios | OSAKA (Japan) und BRISBANE, Kalifornien--(BUSINESS WIRE)--Mrz 9, 2021-- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) („Takeda“) meldete heute die Optionsausübung zur Übernahme von Maverick Therapeutics, Inc., einem privaten b... |
| 09.03.2021 | Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio | OSAKA, Japan & BRISBANE, Calif.--(BUSINESS WIRE)--Mar 9, 2021-- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced the exercise of its option to acquire Maverick Therapeutics, Inc. a private biopharma... |
| 13.08.2017 | MPM Capital-backed Maverick Therapeutics Appoints James Scibetta as CEO | BRISBANE, Calif.–(BUSINESS WIRE)–Maverick Therapeutics Inc., a private immuno-oncology company pioneering advances in redirected T cell therapeutics, announced the appointment of James S. Scibetta as Chief Executive Officer and a member of ... |
| 13.08.2017 | MPM Capital-backed Maverick Therapeutics Appoints James Scibetta as CEO | BRISBANE, Calif.–(BUSINESS WIRE)–Maverick Therapeutics Inc., a private immuno-oncology company pioneering advances in redirected T cell therapeutics, announced the appointment of James S. Scibetta as Chief Executive Officer and a member of ... |
| - | Takeda va racheter Maverick Therapeutics pour faire progresser les thérapies à base d’activateurs de lymphocytes T pour les tumeurs solides et élargir son portefeuille novateur dans l’immuno-oncologie... | OSAKA, Japon, et BRISBANE, Californie--(BUSINESS WIRE)--mars 9, 2021-- Takeda Pharmaceutical Company Limited ( TSE : 4502 ; NYSE : TAK ) (“Takeda”) a annoncé aujourd’hui l’exercice de son option pour acquérir Maverick Therapeutics, Inc., un... |